



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Anti-HIV-1 gp120 Monoclonal (HJ16)

**Catalog Number:** 12138

**Lot Number:** 140407

**Release Category:** C

**Provided:** 100 µg (~16 µL at 6.3 mg/mL) in PBS, sterile, no preservatives

**Host:** Human

**Special Characteristics:** Recombinant human monoclonal antibody produced in 293F cells; purified by protein A affinity chromatography. Neutralizes preferentially Tier-2 HIV-1 variants. Epitope is conformational and located in the CD4 binding site.

**Recommended Storage:** Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

**Contributor:** Dr. Antonio Lanzavecchia

**Isotype:** IgG1 kappa

**References:**  
Corti, D., J. P. M. Langedijk, A. Hinz, M. S. Seaman, F. Vanzetta, B. M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla-Jhagjhoorsingh, B. Willems, M. J. Zekveld, H. Dreja, E. O'Sullivan, C. Pade, C. Orkin, S. A. Jeffs, D. C. Montefiori, D. Davis, W. Weissenhorn, A. McKnight, J. L. Heeney, F. Sallusto, Q. J. Sattentau, R. A. Weiss, and A. Lanzavecchia. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. U.S. Patent 1. PLoS ONE 5:e8805.  
Pietzsch, J., J. F. Scheid, H. Mouquet, F. Klein, M. S. Seaman, M. Jankovic, D. Corti, A. Lanzavecchia, and M. C. Nussenzweig. 2010. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. U.S. Patent 9. The Journal of experimental medicine 207:1995-2002.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (HJ16), from Dr. Antonio Lanzavecchia." Also include the references cited above in any publications.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Antonio Lanzavecchia and Dr. Davide Corti, Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland, Email: [davide.corti@irb.unisi.ch](mailto:davide.corti@irb.unisi.ch), before the reagent can be released.**

**Last Updated**

September 28, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.